DUBLIN--(BUSINESS WIRE)--The "Anti-Obesity Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2024.
This report analyzes the worldwide markets for Anti-Obesity Drugs in US$ Million.
The report profiles 25 companies including many key and niche players such as:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- GlaxoSmithKline PLC (UK)
- Eisai Co. Ltd. (Japan)
- Novo Nordisk A/S (Denmark)
- Rhythm Pharmaceuticals (USA)
- VIVUS Inc. (USA)
Key Topics Covered
1. Introduction, Methodology & Product Definitions
2. Industry Overview
3. Growth Drivers and Market Trends
- Alarming Rise in Global Obesity Levels - The Major Growth Factor
- Classification of BMI
- Exponential Increase in Urban Population
- Rising Incidence of Chronic Diseases Associated with Obesity Drive the Market Expansion
- Growing Middle Class Population to Drive the Market Growth
- Childhood Obesity - A Market with Unmet Needs
- Commercial Weight-Loss Companies Foray into the Market
- Online Drug Stores Boost Sales
- Barriers to Development of Effective Drugs
- Regulatory Additions - A Barrier to Entry?
- High Drug Development Costs - A Major Setback
- Weight Loss Alternatives - A Market Dampener
4. Select Research Initiatives
5. Obesity - An Introduction
6. Anti-Obesity Drugs - An Insight
7. Competitive Landscape
7.1 Focus on Select Global Players
7.2 Recent Industry Activity
8. Global Market Perspective
Total Companies Profiled: 25 The United States (9)
- Japan (2)
-
Europe (8)
- Germany (1)
- The United Kingdom (1)
- Italy (1)
- Rest of Europe (5)
- Asia-Pacific (Excluding Japan) (6)
For more information about this report visit https://www.researchandmarkets.com/research/7pmxl6/antiobesity?w=4